Equities

MustGrow Biologics Corp

MustGrow Biologics Corp

Actions
  • Price (CAD)1.83
  • Today's Change0.02 / 1.10%
  • Shares traded11.08k
  • 1 Year change+59.13%
  • Beta1.3474
Data delayed at least 15 minutes, as of Nov 25 2024 20:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MustGrow Biologics Corp. is a Canada-based agricultural biotechnology company. The Company is engaged in developing natural biological products derived from mustard seed to support sustainable farming. Its solutions provide alternatives to banned or restricted synthetic chemicals and fertilizers, promoting organic farming and soil health improvement. The Company develops mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Its TerraSante is Organic Materials Review Institute (OMRI Listed) and Organic Input Material (OIM) registered biofertility product in California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSante provides mustard proteins and carbohydrates to feed the soil microbes. Its TerraMG is an organic plant extract from mustard used to help treat diseases and insect pests, such as nematodes.

  • Revenue in CAD (TTM)4.71m
  • Net income in CAD-423.96k
  • Incorporated2014
  • Employees0.00
  • Location
    MustGrow Biologics Corp1005-201 1st Ave SSaskatoon S7K 1J5CanadaCAN
  • Phone+1 (306) 668-2652
  • Websitehttps://mustgrow.ca/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nurexone Biologic Inc0.00-5.79m53.16m8.00--13.80-----0.1115-0.11150.000.05360.00-------183.97-213.78-235.34-596.97-----------187.270.0096------55.45------
ZYUS Life Sciences Corp428.00k-36.83m62.49m2.00--3.97--146.00-0.5247-0.52470.00610.21920.00740.0750.5757---63.34-57.88-88.37-71.1946.50-16.16-8,604.67-10,367.370.1593-35.940.3955--17.79213.99-72.73------
Satellos Bioscience Inc0.00-28.53m85.07m12.00--4.13-----0.2528-0.25280.000.18160.00----0.00-78.28-107.22-85.23-136.58------------0.00-------40.33--459.46--
MustGrow Biologics Corp4.71m-423.96k89.92m0.00--25.23--19.08-0.0078-0.00780.09270.07260.9337--32.60---8.40-50.41-11.41-59.28-----9.00-298.734.84--0.1215--72,619.13372.5487.84------
Oncolytics Biotech Inc0.00-27.64m102.55m29.00--11.15-----0.3644-0.36440.000.11750.00-------78.58-81.99-104.96-97.25------------0.1051-------11.75---40.52--
Medicenna Therapeutics Corp0.00-26.68m122.76m16.00--6.42-----0.3747-0.37470.000.26030.00----0.00-87.95-54.93-98.62-60.91-----------2.200.0087-------153.44------
Data as of Nov 25 2024. Currency figures normalised to MustGrow Biologics Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.